Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-000683-24

Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in the second year of life

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate the non-inferiority of Varilrix HSA-free vaccine as compared to Varilrix vaccines in terms of geometric mean titers (GMTs) of varicella antibodies 43 - 57 days after the first dose vaccination


Critère d'inclusion

  • Primary vaccination against varicella in healthy children in their second year of life